Table 1.

Patients Characteristics in Training Cohort and Validation Cohort

Variables	No. of Patients (%)		p-value
	Training Cohort	Validation Cohort
Age			0.25
<60	100 (50%)	43 (43%)
≥60	100 (50%)	57 (57%)
Sex			0.29
Male	157 (78.1%)	73 (73%)
Female	43 (21.4%)	27 (27%)
Marital			0.82
Married	193 (96.5%)	97 (97%)
Unmarried	7 (3.5%)	3 (3%)
BMI			0.72
BMI<18.5	10 (5%)	3 (3%)
18.5≥BMI<25	116 (58%)	59 (59%)
BMI≥25	75 (37%)	38 (38%)
Smoking History			0.39
No	68 (34%)	39 (39%)
Yes	132 (66%)	61 (61%)
Smoking Index			0.87
<800	126 (63%)	62 (62%)
≥800	74 (37%)	38 (38%)
KPS			0.13
≥90	114 (57%)	66 (66%)
<90	86 (43%)	34 (34%)
T Stage			0.99
T1-T2	82 (41%)	41 (41%)
T3-T4	118 (59%)	59 (59%)
N Stage			0.94
N0-N2	103 (51.5%)	52 (52%)
N3	97 (48.5%)	48 (58%)
Brain Metastasis			0.10
No	138 (69%)	78 (78%)
Yes	62 (31%)	22 (22%)
Liver Metastasis			0.6
No	138 (69%)	70 (70%)
Yes	62 (31%)	30 (30%)
Bone Metastasis			0.86
No	138 (69%)	66 (66%)
Yes	62 (31%)	34 (34%)
Thoracic Radiotherapy			0.44
No	137 (68.5%)	64 (64%)
Yes	63 (31.5%)	36 (36%)
Pre-ALB			0.16
≤40	56 (28%)	36 (36%)
>40	144 (72%)	64 (64%)
Pre-ALP			0.16
≤100	89 (44.5%)	36 (36%)
>100	111 (55.5%)	64 (64%)
Pre-AAPR			0.74
≤0.52	126 (63%)	61 (61%)
>0.52	74 (37%)	39 (39%)
Post-ALB			0.06
≤40	65 (32.5%)	22 (22%)
>40	135 (67.5%)	78 (78%)
Post-ALP			0.93
≤100	145 (72.5%)	72 (72%)
>100	55 (27.5%)	28 (28%)
Post-AAPR			0.46
≤0.52	105 (52.5%)	48 (48%)
>0.52	95 (47.5%)	52 (52%)

Abbreviations: KPS, Karnofsky performance score; BMI, body mass index; AAPR, albumin-to-alkaline phosphatase ratio.